deltatrials
Terminated PHASE1 NCT00313456

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Sponsor: Agennix

Conditions Prostate Cancer Tumors
Interventions Satraplatin
Updated 6 times since 2017 Last updated: May 9, 2012 Started: Mar 31, 2006 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

A PHASE1 clinical study on Prostate Cancer and Tumors, this trial is terminated or withdrawn. The trial is conducted by Agennix and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agennix
Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Nashville, United States